In conclusion, the assessed panel of markers (apoCIII, MPO, oxidized-apoAI, ceruloplasmin, and PON1) correlates with the reduced anti-inflammatory potential of HDL2 and HDL3 (mostly HDL3 from ACS) isolated from ACS and SA patients and can discriminate between these groups of CAD patients. The gene discussed is PON1; the disease is coronary artery disorder.